Lee Benjamin J
Department of Pharmacy, Chao Family Comprehensive Cancer Center, University of California Irvine Health, 101 The City Drive South, Building 23, Room 275, Orange, CA 92868, USA.
Department of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California, Irvine, Irvine, CA, USA.
Ther Adv Hematol. 2024 Apr 16;15:20406207241245517. doi: 10.1177/20406207241245517. eCollection 2024.
Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening, hyperinflammatory syndrome for which etoposide-based regimens have historically been the standard of care. Recent reports have described positive outcomes with the utilization of ruxolitinib or anakinra although these studies are often limited to small samples.
We aimed to compare the efficacy of ruxolitinib, anakinra, and etoposide-based therapies for the management of HLH in adult patients.
We performed a population-based, multicenter, retrospective cohort study utilizing the TriNetX Networks database.
Adult patients (⩾18 years) diagnosed with HLH who received first-line treatment with ruxolitinib, anakinra, or etoposide between 2008 and 2023 were analyzed. The primary endpoint was overall survival (OS) at 1 year. A 1:1 propensity-score matching analysis was utilized.
Anakinra ( = 0.020) but not ruxolitinib ( = 0.19) resulted in a significantly higher 1-year OS when compared with etoposide-based therapies.
Anakinra is effective for the management of adult patients with HLH.
噬血细胞性淋巴组织细胞增生症（HLH）是一种罕见的危及生命的高炎症综合征，基于依托泊苷的治疗方案一直是其历史上的标准治疗方法。最近的报告描述了使用鲁索替尼或阿那白滞素取得的阳性结果，尽管这些研究通常限于小样本。
我们旨在比较鲁索替尼、阿那白滞素和基于依托泊苷的疗法对成年HLH患者的治疗效果。
我们利用TriNetX网络数据库进行了一项基于人群的多中心回顾性队列研究。
分析了2008年至2023年间诊断为HLH并接受鲁索替尼、阿那白滞素或依托泊苷一线治疗的成年患者（≥18岁）。主要终点是1年总生存期（OS）。采用1:1倾向评分匹配分析。
与基于依托泊苷的疗法相比，阿那白滞素（P = 0.020）而非鲁索替尼（P = 0.19）导致1年OS显著更高。
阿那白滞素对成年HLH患者的治疗有效。
